Efficacy of budesonide/formoterol inhalation powder in treating viral pneumonia in children

Table 1 Comparison of general information between the two groups of pediatric viral pneumonia patients treated with different methods

Group	Gender		Age	Duration of illness
	Male	Female
Control group (n = 30)	15	15	4.83 ± 1.42	5.77 ± 1.33
Observation group (n = 30)	17	13	4.90 ± 1.54	5.80 ± 1.19
t	0.510		-0.175	-0.102
P value	0.612		0.862	0.919

Table 2 Comparison of pulmonary-function-related indicators between the two groups of pediatric viral pneumonia patients treated with different methods

Group	FVC (L)		FEVl (L)		FEVl/FVC (%)		PEF (L/min)
	Before	After	Before	After	Before	After	Before	After
Control group (n = 30)	2.09 ± 0.31	2.39 ± 0.39a	1.66 ± 0.22	2.14 ± 0.37a	54.53 ± 7.14	76.11 ± 7.49a	254.28 ± 22.22	319.11 ± 21.63a
Observation group (n = 30)	2.04 ± 0.41	3.10 ± 0.42a	1.69 ± 0.31	3.08 ± 0.35a	54.18 ± 6.55	83.59 ± 5.17a	253.73 ± 23.75	352.50 ± 14.89a
t	0.428	-6.801	-0.466	-10.084	0.198	-4.509	0.547	0.040
P value	0.663	< 0.001	0.643	< 0.001	0.844	< 0.001	0.927	< 0.001

^aP < 0.05 vs before treatment. FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 s; PEF: Peak expiratory flow.

Table 3 Comparison of inflammatory-cytokine-related indicators between the two groups of pediatric viral pneumonia patients treated with different methods

Group	IL-6 (U/L)		hs-CRP (mg/L)
	Before	After	Before	After
Control group (n = 30)	35.97 ± 4.27	26.37 ± 3.46a	40.53 ± 5.24	25.23 ± 3.09a
Observation group (n = 30)	35.54 ± 4.50	17.21 ± 2.25a	39.28 ± 3.37	18.15 ± 3.37a
χ2/t	0.375	12.145	1.062	8.478
P value	0.709	< 0.001	0.293	< 0.001

^aP < 0.05 vs before treatment. IL-6: Interleukin-6; hs-CRP: High-sensitivity C-reactive protein.

Table 4 Comparison of CD4⁺/CD8⁺, Th1/Th2, and Th17/Treg between the two groups of pediatric viral pneumonia patients treated with different methods

Group	CD4+/CD8+		Th1/Th2		Th17/Treg
	Before	After	Before	After	Before	After
Control group (n = 30)	0.92 ± 0.05	1.05 ± 0.11a	5.59 ± 0.45a	7.56 ± 0.39a	0.82 ± 0.07a	0.72 ± 0.13a
Observation group (n = 30)	0.91 ± 0.04	1.28 ± 0.15a	5.50 ± 0.45a	6.51 ± 0.30a	0.84 ± 0.05a	0.63 ± 0.07a
χ2/t	1.113	-6.522	0.819	11.601	-1.345	3.354
P value	0.270	< 0.001	0.416	< 0.001	0.184	0.002

^aP < 0.05 vs before treatment.

Table 5 Comparison of clinical efficacy between the two groups of pediatric viral pneumonia patients treated with different methods

Group	Cure	Significant improvement	Effective	Ineffective	Total effective
Control group (n = 30)	13	9	6	2	28
Observation group (n = 30)	9	10	6	5	25